Slide 1: Interim Report Q3 2024
Interim Report Q3 2024 November 14, 2024 © Copyright BioPorto | 1
Slide 2: Forward-looking Statements
Forward-looking Statements References herein to this presentation shall mean and include this document, to publicly update or revise forward-looking statements to reflect subsequent any oral presentation accompanying this document provided by BioPorto A/S events or circumstances after the date of th
Slide 3: Highlights from Q3 2024
Highlights from Q3 2024
Slide 4: Highlights from the Q3 2024 report
Highlights from the Q3 2024 report T O TA L R E V E N U E ( Q 1 - Q 3 2 0 2 4 ) • 36% increase in US NGAL revenue YTD drives solid total revenue DKK 28.3 million growth. An increase of 16% over same period last year • Expansion of commercial activities globally to convert awareness to demand for NGA
Slide 5: Strong execution of Phase I expected to continue
Strong execution of Phase I expected to continue Targets for period until Status after Q3 2024 Remaining part of 2024 mid-2025 Key Objectives: Status: Q4 2024: • Initiate usage in Pediatrics/young ✓ Continued growth in US revenue with • Continued collaboration with adults (US). first standing order.
Slide 6: Important future milestones
Important future milestones Fundraising to fund First patient US First patient US Last patient US FDA submission Exp. US clearance FDA clearance process enrollment for enrollment for enrollment for of ProNephro for ProNephro AKI for ProNephro AKI adult study adult study adult study AKI (NGAL) for (N
Slide 7: Strategic Roadmap
Strategic Roadmap
Slide 8: AKI Diagnostics Market Growing at +5% yearly driven by changing paradigm
AKI Diagnostics Market Growing at +5% yearly driven by changing paradigm • The AKI market is driven by advances in early detection and diagnostic technologies. McKinsey notes a need to move to preventative care. ROW adult US adult • Recent advancements are transforming TAM TAM paradigm from Serum Cr
Slide 9: NGAL assays designed to run on major clinical chemistry instruments
NGAL assays designed to run on major clinical chemistry instruments High-Value Diagnostic Price Point High margins even at today’s scale No investment in capital equipment © Copyright BioPorto | 9
Slide 10: Strategic initiatives and milestones towards 2029
Strategic initiatives and milestones towards 2029 Phase I Phase II Phase III 2024 – Jun 2025 Jul 2025 – Dec 2026 2027- 2029 Pediatric Indication Approved Pediatric Instrument Expansion Clearance Adult Indication Executed (FDA|IVDR) Key Objectives: Key Objectives: Key Objectives: • Initiate usage in
Slide 11: Targeting USD +100 million revenue in 2029 and profitability by 2026
Targeting USD +100 million revenue in STRATEGIC & FINANCIAL 2029 and profitability by 2026 OBJECTIVES • Revenue: USD +100m • Increasing profitability • Cash flow positive • Until 2026 – 3-4x 2024 Revenue revenue and build cash Adj. EBITDA trendline flow positive & EBITDA neutral operations by expand
Slide 12: Execution in Q3 2024
Execution in Q3 2024
Slide 13: Strengthening of commercial activities is building pipeline
Strengthening of commercial activities is building pipeline • Further expansion of business development and sales staff in US and Europe. • High activity in converting NGAL awareness to actual NGAL Test demand is expanding pipeline both in the US and Europe. • Conference attendance and a high level
Slide 14: BioPorto's NGAL presence today
BioPorto’s NGAL presence today US News Best Children’s Hospitals 2024-2025 Honor Roll ✓ Boston Children’s Hospital ✓ Children’s Hospital Colorado ✓ Children’s Hospital of Philadelphia 7 Current ✓ Cincinnati Children’s NGAL Users ✓ Nationwide Children’s Hospital ✓ Rady Children’s Hospital ✓ Seattle C
Slide 15: New Global Partnership with Beckman Coulter for distribution of NGAL Tests
New Global Partnership with Beckman Coulter for distribution of NGAL Tests • First step in expansion of distribution agreements which is a cornerstone in BioPorto’s commercial strategy for NGAL Test A global leader in clinical products. diagnostics, with a history that dates back more • The agreemen
Slide 16: Enrolment of patients for adult ProNephro AKI (NGAL) commenced in October 2024
Enrolment of patients for adult ProNephro AKI (NGAL) commenced in October 2024 • First patient for first of two US clinical studies for adult usage of ProNephro AKI (NGAL) for AKI enrolled in October 2024 at Massachusetts General Hospital – well ahead of original schedule. • First study will determi
Slide 17: Financial results in Q3 2024
Financial results in Q3 2024
Slide 18: Total revenues up 16% YTD Q3 2024 – Growth in all product groups
Total revenues up 16% YTD Q3 2024 – Growth in all product groups Annual Revenue by Product Group Revenue by Quarter 2023 2024 Total NGAL Tests Antibodies Others 28.3 (+16%) 9,5 9,7 9,2 24.4 8,6 8,0 7,7 Q3 6,6 Q3 18.3 (+20%) 15.2 DKKm Q3 DKKm Q2 Q2 Q3 Q2 7.9 8.4 (+7%) Q2 Q3 Q3 Q1 Q1 Q2 Q2 Q1 Q1 1.3 1
Slide 19: NGAL sales increasing by 17% in the last twelve months (LTM)
NGAL sales increasing by 17% in the last twelve months (LTM) Total NGAL test sales by Quarter (LTM, DKKm) • Continued strong development in US sales of NGAL products (RUO). +17% • In YTD Sep 2024 US NGAL sales makes up 40% of total revenue. • Total NGAL revenues makes up 65% of total Q3 2021 Q4 2021
Slide 20: Adj. EBITDA loss increased compared to last year
Adj. EBITDA loss increased compared to last year • EBITDA loss in Q3 2024 Adjusted EBITDA and cash position (DKKm) increased by DKK 9.9 million Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 compared to last year. 103,9 • Sales and marketing cost increased due to higher 76,3 activities and organizational 6
Slide 21: Financial Outlook for 2024
Financial Outlook for 2024
Slide 22: 2024 Financial Outlook
2024 Financial Outlook Key revenue drivers for 29% revenue growth for the full year Revenue Adj. EBITDA • Increased sales of NGAL products, DKK ~40 Million DKK (75)-(90) Million primarily in the US. USD (11)-(13) Million USD 6 Million EBITDA drivers • Increased US marketing spending for ProNephro AK
Slide 23: Q&A
Q&A November 14, 2024 - Interim Report, Q3 2024